PCI Pharma Services’ Bedford, New Hampshire Location Successfully Completes International Coalition of Medicines Regulatory Authorities Inspection

Contributed by: Business Wire

Logo

Images

Business Wire embedded0

Tags

Medical Supplies

Packaging

Transport

Manufacturing

Biotechnology

Health

Pharmaceutical

General Health

Logistics/Supply Chain Management

PCI Pharma Services

More Like This

PCI Pharma Services is investing more than $365 million in infrastructure supporting the clinical and commercial-scale final assembly and packaging of drug-device combination products utilizing advanced drug delivery systems, with an emphasis on injectable formats. (Photo: Business Wire)

PCI Pharma Services Invests Over $365 Million in EU, US Facilities for Clinical and Commercial Supply of Advanced Drug Delivery and Drug-Device Combination Products

PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea.

PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea

PCI Pharma Services enhances US manufacturing of prefilled syringes & cartridges through acquisition of Ajinomoto Althea.

Part of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes & Cartridges

The report discloses PCI's performance, targets, and strategy to achieve nine identified impact categories. (Photo: Business Wire)

Leading CDMO PCI Pharma Services Releases Inaugural Comprehensive ESG Report

Aldena Therapeutics Selects PCI Pharma Services to Manufacture and Distribute Innovative Investigational Treatment for Dermatological Diseases

CARBOGEN AMCIS Secures GMP Certification After Successful ANSM Inspection for its Aseptic Drug Product Manufacturing Site

PR Newswire associated0

PIRAMAL PHARMA SOLUTIONS COMMEMORATES OPENING OF ITS ADC MANUFACTURING EXPANSION IN GRANGEMOUTH, SCOTLAND

C3i Center Inc is First CDMO in Canada to Receive Approval for a Drug Establishment License to Commercially Produce Cell Therapy Drug Products